New depression pill takes first step in human safety trial
NCT ID NCT07371065
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This early-stage study tests a new tablet called LY03021 in 98 healthy adults aged 18 to 45. The main goal is to check the drug's safety and how the body processes it. This is a first step before testing the medicine in people with depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
No. 604 Lingling Road, Shanghai
Shanghai, China
Conditions
Explore the condition pages connected to this study.